[A15-56] Pembrolizumab - Addendum to Commission A15-33
Last updated 05.10.2017
Commission awarded on 22.12.2015 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.